Abstract Number: 847 • 2012 ACR/ARHP Annual Meeting
Enhanced ROCK Activation in Patients with Systemic Lupus Erythematosus
Background/Purpose: The Rho GTPases, Rac and RhoA, play a key role in immune responses by regulating both cytoskeletal reorganization and gene expression. RhoA exerts many…Abstract Number: 848 • 2012 ACR/ARHP Annual Meeting
Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are characterised by hyperactive T-cells that provide help to auto-reactive B-cells. Underlying this hyperactivity are alterations in the…Abstract Number: 849 • 2012 ACR/ARHP Annual Meeting
The Risk of Cardiovascular Disease in Systemic Sclerosis: A Population-Based Cohort Study
Background/Purpose: Recent studies show that the prevalence of subclinical atherosclerosis is increased in individuals with systemic sclerosis (SSc). An accurate understanding of cardiovascular disease…Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…Abstract Number: 851 • 2012 ACR/ARHP Annual Meeting
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and…Abstract Number: 852 • 2012 ACR/ARHP Annual Meeting
C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis
ABSTRACT:Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In…Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…Abstract Number: 819 • 2012 ACR/ARHP Annual Meeting
Trajectories of Change in Physical Function: Effects On Fractures and Mortality
Background/Purpose: Prior studies have identified poor physical function as a risk factor for fractures and mortality. However, these studies did not consider change in physical…Abstract Number: 820 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk for both fracture (fx) and cardiovascular disease (CVD) and there is increasing evidence establishing a…Abstract Number: 821 • 2012 ACR/ARHP Annual Meeting
Association of Serum Uric Acid and Incident Fractures in Elderly Men
Background/Purpose: Normal mineral metabolism is critical for skeletal integrity. Uric acid (UA) is produced from purines by the enzyme xanthine oxidase, and elevated levels may…
ACR Meeting Abstracts